Protein and peptide nanoparticles for drug delivery / edited by Rossen Donev ; contributors, Priyanka Bhatt [and twenty-seven others].

Format:

Book

Contributor:

Donev, Rossen, editor.

Bhatt, Priyanka, contributor.

Series:

Advances in protein chemistry and structural biology ; Volume 98.

Advances in Protein Chemistry and Structural Biology, 1876-1623 ; Volume 92

Language:

English

Subjects (All):

Nanoparticles.

Peptide drugs--Dosage forms.

Peptide drugs.

Protein drugs--Dosage forms.

Protein drugs.

Physical Description:

1 online resource (386 p.)

Edition:

First edition.

Place of Publication:

Amsterdam, [Netherlands] : Academic Press, 2015.

Language Note:

English

Summary:

Linda L. Clark traces several generations of French women in public administration, examining public policy, politics and attitudes, and women's work and education. This history of professional women in positions of administrative responsibility illuminates women's changing relationship to the public sphere in France since the Revolution of 1789.

Contents:

Front Cover; Protein and Peptide Nanoparticles for Drug Delivery; Copyright; Contents; Contributors; Preface; References; Chapter One: Protein- and Peptide-Drug Conjugates: An Emerging Drug Delivery Technology; 1. Introduction; 2. Protein-Drug Conjugates; 2.1. Albumin-drug conjugates; 2.2. Transferrin-drug conjugates; 2.3. Gelatin-drug conjugates; 2.4. Antibody-drug conjugates; 2.5. Other protein-drug conjugates; 3. Peptide-Drug Conjugates; 3.1. RGD peptide-drug conjugates; 3.2. Cell penetrating peptide-drug conjugates; 4. Strategies for Chemical Conjugation; 4.1. Linker technologies

4.1.1. Cleavable linkers4.1.2. Noncleavable linkers; 5. Challenges; 6. Future Perspective; 7. Conclusion; References; Chapter Two: Modifications of Natural Peptides for Nanoparticle and Drug Design; 1. Introduction; 2. Role of Nanoparticles in Peptide Drug Delivery; 3. Cell-Penetrating Peptides; 3.1. Structure and properties; 3.1.1. Cationic CPPs; 3.1.2. Amphipathic CPPs; 3.1.3. Hydrophobic CPPs; 3.2. Applications in nanoparticle delivery; 3.2.1. Tat peptide; 3.2.2. Penetratin; 3.2.3. MPG/Pep-1; 3.2.4. Antimicrobial peptides; 4. Antimicrobial Peptides; 4.1. Sequence modifications

4.2. Nanoparticle delivery strategies5. Peptide Toxins; 5.1. Mechanisms of action; 5.2. Therapeutic applications; 5.2.1. Amphibian toxins; 5.2.2. Bee venom; 5.2.3. Scorpion venom; 5.2.4. Snake venom; 6. Conclusion; References; Chapter Three: Hybrid Protein-Synthetic Polymer Nanoparticles for Drug Delivery; 1. Introduction; 2. Nanoparticles Derived from Polymer(s) and Covalently Bound Protein(s); 2.1. Hybrid micelles derived from copolymers of PEG and PGlu; 2.2. Hybrid nanoparticles based on (bio)degradable polyesters; 2.3. Hybrid nanoparticles based on nondegradable polymers

3. Hybrid Nanoparticles Based on Electrostatic Interactions Between Proteins/Peptides and Synthetic Polyelectrolytes4. Conclusions; References; Chapter Four: Efficient Delivery of Therapeutic Agents by Using Targeted Albumin Nanoparticles; 1. Introduction; 2. Albumin Nanoparticles' Fabrication Methods; 3. Albumin-Nanoparticles-Targeting Strategies; 4. Albumin Nanoparticles as a Drug Delivery Carrier; 4.1. Chemotherapeutic agents; 4.1.1. Paclitaxel; 4.1.2. Doxorubicin; 4.1.3. Other drugs; 4.2. Biological macromolecules; 5. Albumin Nanoparticles Marketed and Under Clinical Trial; 6. Conclusions

ReferencesChapter Five: Vasoactive Intestinal Peptide (VIP) Nanoparticles for Diagnostics and for Controlled and Targeted Drug Delivery; 1. Introduction; 2. Structural Basis for the Neuropeptide VIP-Targeted Drug Delivery; 3. Functional Bases for the Neuropeptide VIP as an Endogenous Lead Compound; 4. Nanotechnology Helps to Solve Key VIPs Druggability Problems; 5. Types of VIP-Engineered Nanoparticles; 5.1. Nanoparticles designed for VIP drug delivery; 5.2. Smart-delivery nanoparticles designed for VIP targeting; 6. Concluding Remarks; Acknowledgments; References

Chapter Six: Implications of Protein- and Peptide-Based Nanoparticles as Potential Vehicles for Anticancer Drugs

Notes:

Description based upon print version of record.

Includes bibliographical references at the end of each chapters and index.

Description based on online resource; title from PDF title page (ebrary, viewed April 11, 2015).

ISBN:

0-12-802870-X

0-12-802828-9

OCLC:

437072994